$100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 17.85% on an annualized basis…
Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Peering Into Regeneron Pharmaceuticals’s Recent Short Interest
Regeneron Pharmaceuticals’s (NYSE:REGN) short percent of float has risen 3.31% since its last report. The company recently reported…
Goldman Sachs Optimistic About Regenxbio’s Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
What’s Going On With FibroGen Stock Tuesday?
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial supply agreement with Regeneron.
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry…
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
Throughout the last three months, 14 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions…
FibroGen Stock Is Surging After The Bell: What’s Going On?
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.
FibroGen Inks Clinical Trial Supply Agreement With Regeneron Pharmaceuticals To Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 And FG-3175, In Combination With LIBTAYO In Upcoming Clinical Trials
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175,
Here’s How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 1.96% on an annualized basis…